CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
A-101 Topical Solution 40%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03224598
NCT03224598Phase 2Completed
CompareCT.gov

A Phase 2 Open Label Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

Aclaris Therapeutics, Inc.·interventional·Posted Jul 21, 2017·Updated Mar 30, 2020

In Brief

A Phase 2 clinical trial evaluating A-101 Topical Solution 40% for Dermatosis Papulosa Nigra. Completed, enrolled 39 participants across 2 sites.

Detailed Summary

Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatosis Papulosa Nigra
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 21, 2017
Enrollment StartJun 26, 2017
Primary CompletionJan 8, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.9 years ago

Interventions

A-101 Topical Solution 40%drug

A-101 Topical Solution 40%